260 related articles for article (PubMed ID: 8438615)
21. Shigella vaccine development: prospective animal models and current status.
Kim YJ; Yeo SG; Park JH; Ko HJ
Curr Pharm Biotechnol; 2013; 14(10):903-12. PubMed ID: 24372251
[TBL] [Abstract][Full Text] [Related]
22. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.
Dharmasena MN; Hanisch BW; Wai TT; Kopecko DJ
Int J Med Microbiol; 2013 Apr; 303(3):105-13. PubMed ID: 23474241
[TBL] [Abstract][Full Text] [Related]
23. Vaccine research and development. New strategies for accelerating Shigella vaccine development.
Wkly Epidemiol Rec; 1997 Mar; 72(11):73-9. PubMed ID: 9115858
[No Abstract] [Full Text] [Related]
24. Classical and novel strategies to develop a
Barel LA; Mulard LA
Hum Vaccin Immunother; 2019; 15(6):1338-1356. PubMed ID: 31158047
[No Abstract] [Full Text] [Related]
25. The large virulence plasmid of Shigella.
Sasakawa C; Buysse JM; Watanabe H
Curr Top Microbiol Immunol; 1992; 180():21-44. PubMed ID: 1505205
[No Abstract] [Full Text] [Related]
26. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
[TBL] [Abstract][Full Text] [Related]
27. [Molecular biology in the pathogenesis of Shigella sp. and enteroinvasive Escherichia coli].
Rico-Martínez MG
Rev Latinoam Microbiol; 1995; 37(4):367-85. PubMed ID: 8900572
[TBL] [Abstract][Full Text] [Related]
28. [On the problem of specific prevention of dysentery. I. Selection of avirulent immunogenic strains of Flexner and Sonne dysentery bacteria].
Belaia IuA
Zh Mikrobiol Epidemiol Immunobiol; 1968 Apr; 45(4):14-9. PubMed ID: 4898256
[No Abstract] [Full Text] [Related]
29. Pathogenesis, genetics of virulence, and immunity in Shigellosis.
Formal SB; Kapfer C; Hale TL
Kansenshogaku Zasshi; 1988 Mar; 62 Suppl():329-42. PubMed ID: 3138359
[No Abstract] [Full Text] [Related]
30. How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
Giersing BK; Porter CK; Kotloff K; Neels P; Cravioto A; MacLennan CA
Vaccine; 2019 Aug; 37(34):4778-4783. PubMed ID: 31358238
[TBL] [Abstract][Full Text] [Related]
31. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
Phalipon A; Tanguy M; Grandjean C; Guerreiro C; Bélot F; Cohen D; Sansonetti PJ; Mulard LA
J Immunol; 2009 Feb; 182(4):2241-7. PubMed ID: 19201878
[TBL] [Abstract][Full Text] [Related]
32. Vaccination against shigellosis: is it the path that is difficult or is it the difficult that is the path?
Phalipon A; Mulard LA; Sansonetti PJ
Microbes Infect; 2008 Jul; 10(9):1057-62. PubMed ID: 18672087
[TBL] [Abstract][Full Text] [Related]
33. [Modern views on the pathogenesis of dysentery: the role of invasion and the toxic action of Shigella].
Pokrovskiĭ VI; Bondarenko VM; Polotskiĭ IuE; Iushchuk ND
Zh Mikrobiol Epidemiol Immunobiol; 1990 May; (5):101-10. PubMed ID: 2201151
[No Abstract] [Full Text] [Related]
34. Experimental approach in studies on pathogenesis of bacillary dysentery--with special references to the invasion of bacilli into intestinal mucosa.
Ogawa H
Acta Pathol Jpn; 1970 Aug; 20(3):261-77. PubMed ID: 4994630
[No Abstract] [Full Text] [Related]
35. [Comparative immunomorphological study of the immunogenic activity of dysentery vaccines produced by different methods].
Belaia IuA; Rukhamina ML; Nguyen ZH
Zh Mikrobiol Epidemiol Immunobiol; 1983 Jul; (7):64-70. PubMed ID: 6353818
[TBL] [Abstract][Full Text] [Related]
36. Immunoprophylaxis against bacillary dysentery by dysentery live vaccine Vadizen (Shigella flexneri T32-Istrati) in children collectivities in SV County.
Bogus L; Ianopol L; Dascălu C; Bende B; Iliescu C; Carliuc V; Meitert T; Pencu E; Ciudin L; Tonciu M
Arch Roum Pathol Exp Microbiol; 1984; 43(3-4):291-8. PubMed ID: 6400302
[No Abstract] [Full Text] [Related]
37. [Immunogenic properties of live lyophilized dysentery vaccine in experiments on monkeys].
Sergeev VV; Mikhaĭlov IF; Gleĭberman SE; Iuditskaia NM; Kavtaradze KN
Zh Mikrobiol Epidemiol Immunobiol; 1968 Nov; 45(11):26-32. PubMed ID: 4980669
[No Abstract] [Full Text] [Related]
38. Live-attenuated Shigella vaccines.
Venkatesan MM; Ranallo RT
Expert Rev Vaccines; 2006 Oct; 5(5):669-86. PubMed ID: 17181440
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine.
DeLaine BC; Wu T; Grassel CL; Shimanovich A; Pasetti MF; Levine MM; Barry EM
Pathog Dis; 2016 Jul; 74(5):. PubMed ID: 27106253
[TBL] [Abstract][Full Text] [Related]
40. O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative.
Chowers Y; Kirschner J; Keller N; Barshack I; Bar-Meir S; Ashkenazi S; Schneerson R; Robbins J; Passwell JH
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2396-401. PubMed ID: 17287349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
